Terms: = Prostate cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
71 results:
1. Tandem CAR-T cells targeting muc1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer.
Wang A; Lv T; Song Y
Cell Immunol; 2023; 391-392():104760. PubMed ID: 37660477
[TBL] [Abstract] [Full Text] [Related]
2. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Higano CS; Cheng HH
Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
[TBL] [Abstract] [Full Text] [Related]
3. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines.
Atobatele AG; Tonoli E; Vadakekolathu J; Savoca MP; Barr M; Kataria Y; Rossanese M; Burhan I; McArdle S; Caccamo D; Verderio EAM
Cell Death Dis; 2023 May; 14(5):317. PubMed ID: 37160910
[TBL] [Abstract] [Full Text] [Related]
4. [Lutetium-177-PSMA in metastasized prostate carcinoma].
van Golen LW; Vogel W; Lam MGEH
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943158
[TBL] [Abstract] [Full Text] [Related]
5. [Lutetium-177-PSMA in metastasized prostate carcinoma].
van Golen LW; Vogel W; Lam MGEH
Ned Tijdschr Geneeskd; 2023 Mar; 166():. PubMed ID: 36927799
[TBL] [Abstract] [Full Text] [Related]
6. Dependence on muc1-C in Progression of Neuroendocrine prostate cancer.
Kufe D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835130
[TBL] [Abstract] [Full Text] [Related]
7. Adoption of Lutetium-
Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
[TBL] [Abstract] [Full Text] [Related]
8. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
Sayar E; Patel RA; Coleman IM; Roudier MP; Zhang A; Mustafi P; Low JY; Hanratty B; Ang LS; Bhatia V; Adil M; Bakbak H; Quigley DA; Schweizer MT; Hawley JE; Kollath L; True LD; Feng FY; Bander NH; Corey E; Lee JK; Morrissey C; Gulati R; Nelson PS; Haffner MC
JCI Insight; 2023 Apr; 8(7):. PubMed ID: 36821396
[TBL] [Abstract] [Full Text] [Related]
9. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in prostate cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract] [Full Text] [Related]
10. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
[TBL] [Abstract] [Full Text] [Related]
11. Chemical Interrogation of Nuclear Size Identifies Compounds with cancer Cell Line-Specific Effects on Migration and Invasion.
Tollis S; Rizzotto A; Pham NT; Koivukoski S; Sivakumar A; Shave S; Wildenhain J; Zuleger N; Keys JT; Culley J; Zheng Y; Lammerding J; Carragher NO; Brunton VG; Latonen L; Auer M; Tyers M; Schirmer EC
ACS Chem Biol; 2022 Mar; 17(3):680-700. PubMed ID: 35199530
[No Abstract] [Full Text] [Related]
12. pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study.
Lin H; Liu Q; Zeng X; Yu W; Xu G
BMC Cancer; 2021 Apr; 21(1):399. PubMed ID: 33849473
[TBL] [Abstract] [Full Text] [Related]
13. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract] [Full Text] [Related]
14. Primary prostate cancer synchronous with renal cell carcinoma: clinical experience and literature review.
Li ZY; Ying CC; Wan ZH; Wang ZS; Li GH; Chen L; Guo YL
Rom J Morphol Embryol; 2020; 61(2):555-561. PubMed ID: 33544809
[TBL] [Abstract] [Full Text] [Related]
15. Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups.
Alshaker H; Mills R; Hunter E; Salter M; Ramadass A; Skinner BM; Westra W; Green J; Akoulitchev A; Winkler M; Pchejetski D
J Transl Med; 2021 Jan; 19(1):46. PubMed ID: 33509203
[TBL] [Abstract] [Full Text] [Related]
16. Nanotechnology in ovarian cancer: Diagnosis and treatment.
Barani M; Bilal M; Sabir F; Rahdar A; Kyzas GZ
Life Sci; 2021 Feb; 266():118914. PubMed ID: 33340527
[TBL] [Abstract] [Full Text] [Related]
17. Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer.
Chang CC; Chao KC; Huang CJ; Hung CS; Wang YC
Mol Med Rep; 2020 Jul; 22(1):185-192. PubMed ID: 32319648
[TBL] [Abstract] [Full Text] [Related]
18. In vivo anti-muc1
Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
[TBL] [Abstract] [Full Text] [Related]
19. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
[TBL] [Abstract] [Full Text] [Related]
20. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Gómez Rivas J; Carrion DM; Alvarez-Maestro M; Cathelineau X; Sanchez-Salas R; Di Lorenzo G; Di Maio M; Paul A; Martinez-Piñeiro L; Sartor O; Saad F; Debruyne F
Minerva Urol Nefrol; 2019 Oct; 71(5):445-456. PubMed ID: 31353876
[TBL] [Abstract] [Full Text] [Related]
[Next]
